Alkermes (ALKS) Free Cash Flow (2010 - 2026)
Alkermes' (ALKS) quarterly Free Cash Flow came in at -$169.8 million in Q1 2026, down 291.47% year-on-year from $88.7 million in Q1 2025, and down 199.85% on a QoQ basis from $170.1 million in Q4 2025.
Alkermes (ALKS) Free Cash Flow (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Free Cash Flow data on file, last reported at -$169.8 million in Q1 2026.
- On a quarterly basis, Free Cash Flow fell 291.47% year-over-year to -$169.8 million in Q1 2026; TTM through Mar 2026 was $221.8 million, a 53.94% decrease from a year earlier, with the FY2025 full-year figure at $480.3 million, up 18.41% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$169.8 million, down from $170.1 million in the prior quarter.
- Over the last five years, Free Cash Flow for ALKS reached as high as $206.0 million in Q2 2023 and fell as low as -$169.8 million in Q1 2026.
- Historically, Free Cash Flow has averaged $61.9 million across 5 years, with a median of $84.4 million in 2025.
- On a YoY basis, Free Cash Flow climbed as much as 1779.21% in 2023 and fell as far as 302.79% in 2023.
- Year by year, Free Cash Flow stood at -$9.0 million in 2022, then surged by 1104.42% to $90.2 million in 2023, then soared by 100.23% to $180.6 million in 2024, then dropped by 5.83% to $170.1 million in 2025, then plunged by 199.85% to -$169.8 million in 2026.
- Per Business Quant data, the three most recent Free Cash Flow figures were -$169.8 million in Q1 2026, $170.1 million in Q4 2025, and $84.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -208.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 291.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -373.37 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 363.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 348.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 144.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -38.00 Mn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | -169.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -169.83 Mn |
| Mar 31, 2026 | -169.83 Mn |
| Dec 31, 2025 | 170.09 Mn |
| Dec 31, 2025 | 170.09 Mn |
| Sep 30, 2025 | 84.36 Mn |
| Sep 30, 2025 | 84.36 Mn |
| Jun 30, 2025 | 137.19 Mn |
| Jun 30, 2025 | 137.19 Mn |
| Mar 31, 2025 | 88.70 Mn |
| Mar 31, 2025 | 88.70 Mn |
| Dec 31, 2024 | 180.62 Mn |
| Dec 31, 2024 | 180.62 Mn |
| Sep 30, 2024 | 73.33 Mn |
| Sep 30, 2024 | 73.33 Mn |
| Jun 30, 2024 | 138.92 Mn |
| Jun 30, 2024 | 138.92 Mn |
| Mar 31, 2024 | 12.77 Mn |
| Mar 31, 2024 | 12.77 Mn |
| Dec 31, 2023 | 90.21 Mn |
| Dec 31, 2023 | 90.21 Mn |